Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MRE11 | P49959 | 1/20 | 0.40 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690748 | 0.89 | ROCK2 (0.52) | MAPK1MAPK14 | |
| SCHEMBL692489 | 0.85 | MAPK14 (0.45) | LMNAMAPK14ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9611041 | 0.83 | MAPK1 (0.57) | LMNAMAPK1MAPK14ALDH1A1HPGD | |
| SCHEMBL692348 | 0.82 | MEN1 (0.49) | EPHX2NR1H4MAPK1MAPK14CYP1A2 | |
| SCHEMBL690828 | 0.82 | SMN1; SMN2 (0.48) | LMNAPPARAALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL692237 | 0.81 | PTPN7 (0.42) | LMNAMAPK1 | |
| SCHEMBL3239497 | 0.81 | KMT2A (0.49) | EPHX2NR1H4HTR2CLMNANPSR1 | |
| SCHEMBL9613113 | 0.79 | MAPK14 (0.46) | LMNAMAPK1MAPK14ALDH1A1HPGD | |
| SCHEMBL690181 | 0.78 | P2RX1 (0.42) | — | |
| SCHEMBL28617395 | 0.78 | CTSL (0.51) | EPHX2NR1H4HTR2CLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560643-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | claimed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | claimed |
| EP-2421528-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | claimed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2560643-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| EP-2421528-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2011-11-24 | — | — | US | disclosed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133596-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | AKR1C2 669/4885AKR1C1 835/4885EPHX2 2358/4885 |
| US-20110288103-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | ORAI1, ATP2A3, ANO1 | AKR1C2 1053/4885AKR1C1 1376/4885EPHX2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.